INMB - Inmune Bio, Inc.
IEX Last Trade
4.49
-0.690 -15.367%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:15:58 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$5.18
-0.69
-13.32%
Fundamental analysis
20%
Profitability
25%
Dept financing
8%
Liquidity
52%
Performance
11%
Performance
5 Days
2.05%
1 Month
-6.46%
3 Months
-7.61%
6 Months
-37.20%
1 Year
-57.32%
2 Year
-36.13%
Key data
Stock price
$4.49
DAY RANGE
$4.40 - $5.18
52 WEEK RANGE
$4.59 - $14.74
52 WEEK CHANGE
-$59.98
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Raymond J. Tesi
Region: US
Website: inmunebio.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: inmunebio.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Recent news